Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi (SNY) Could Be a Great Choice
01:19pm, Wednesday, 21'st Jun 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?
2 Biopharma Stocks Making Big Moves Tuesday
08:41am, Tuesday, 20'th Jun 2023
Markets eased lower in premarket trading to open the week Tuesday morning. Dice Therapeutics received an acquisition bid from Eli Lilly.
2 Best Biotech Stocks to Buy Right Now
10:07am, Friday, 16'th Jun 2023
These European pharma giants have long-established records of success. AstraZeneca has 12 medicines that are on track to become blockbusters.
US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
04:32pm, Thursday, 08'th Jun 2023
The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.
FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection
04:23pm, Thursday, 08'th Jun 2023
Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY, +1.30% and AstraZeneca AZN, +1.28% to protect infants from resp
International Wide-Moat Stocks On Sale - The June 2023 Heat Map
09:51pm, Wednesday, 07'th Jun 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued. We share the heat map of the most investable candida
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
02:34pm, Wednesday, 07'th Jun 2023
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy
10:29am, Tuesday, 06'th Jun 2023
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infectio
Are You Looking for a High-Growth Dividend Stock?
12:56pm, Monday, 05'th Jun 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
01:16pm, Wednesday, 31'st May 2023
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Sanofi announces positive data for frexalimab product to treat multiple sclerosis
01:11am, Wednesday, 31'st May 2023
French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sc
2 Bear Market Defying Stocks to Buy in May
07:45am, Monday, 22'nd May 2023
Sanofi's wide lineup of medicines across several therapeutic areas makes it attractive. Axsome Therapeutics is rising in prominence thanks to an exciting pipeline.
Sanofi: smoker's lung drug benefit was swift and sustained in trial
02:20am, Monday, 22'nd May 2023
The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat "smoker's lung" and lasted for the duration of the 1-year study, French drugmaker Sanofi s
5 Things to Know Before Markets Open
07:25am, Friday, 19'th May 2023
President Biden said he was confident that negotiators would reach a deal on the debt ceiling and Fed Chair Jerome Powell is set to speak on monetary policy. Here's what investors need to know today.
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
04:50am, Friday, 12'th May 2023
Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. The results could stoke Sanofi stock.
